Abstract | BACKGROUND: METHODS: RESULTS: The overall response rate was 79·3% (39 CR: 67·2%; and 7 PR: 12·1%); 12 patients (20·1%) were non-responders. The 5-year overall survival rate was 77·6%; five initially responder patients relapsed within the first 5 years of follow-up and underwent salvage therapy. CONCLUSION: The TECA conditioning regimen for ASCT in HL results in a good anti-HL effect, positive response to treatment and high 5-year overall survival rate. It was also well tolerated and did not induce excessive toxicity, suggesting that TECA may be a very useful conditioning regimen for HL.
|
Authors | Mauro Di Ianni, Stelvio Ballanti, Giuseppe Iodice, Antonia Reale, Franca Falzetti, Olivia Minelli, Gabriella Serio, Massimo F Martelli, Franco Dammacco, Angelo Vacca, Roberto Ria |
Journal | Hematology (Amsterdam, Netherlands)
(Hematology)
Vol. 17
Issue 1
Pg. 23-7
(Jan 2012)
ISSN: 1607-8454 [Electronic] England |
PMID | 22549444
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Bleomycin
- Vinblastine
- Etoposide
- Dacarbazine
- Doxorubicin
- Thiotepa
- Carboplatin
|
Topics |
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Bleomycin
(administration & dosage)
- Carboplatin
(administration & dosage)
- Dacarbazine
(administration & dosage)
- Disease-Free Survival
- Doxorubicin
(administration & dosage)
- Etoposide
(administration & dosage)
- Hematopoietic Stem Cell Transplantation
(methods)
- Hodgkin Disease
(drug therapy, surgery)
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Survival Rate
- Thiotepa
(administration & dosage)
- Transplantation Conditioning
(methods)
- Transplantation, Autologous
- Treatment Outcome
- Vinblastine
(administration & dosage)
- Young Adult
|